Atossa Therapeutics (ATOS) vs Celularity (CELU)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Celularity (CELU) has outperformed Atossa Therapeutics (ATOS) over the past year, losing 73.5% versus a loss of 86.4%. Over five years, ATOS leads with a -95.3% price change compared with -99.3% for CELU. Atossa Therapeutics is the larger company by market cap ($15.9 million vs $15.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATOS | CELU |
|---|---|---|
| Share price | $1.60 | $0.463 |
| Market cap | $15.92M | $15.02M |
| 1-day change | -8.86% | -1.05% |
| YTD return | -81.98% | -58.29% |
| 1-year return | -86.37% | -73.54% |
| 5-year return | -95.34% | -99.31% |
| EPS (TTM) | $-3.92 | $-1.69 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $26.55M |
| Revenue growth (YoY) | — | -51.03% |
| Net income (latest FY) | $-34.77M | $-91.72M |
| Gross margin | — | 24.39% |
| Operating margin | — | -230.92% |
| Net margin | — | -345.45% |
| 52-week high | $14.85 | $2.55 |
| 52-week low | $1.59 | $0.42 |
| Distance from 52-week high | -89.26% | -81.84% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +1091.22% | — |
| Average volume | 68.00K | 3.95M |
| Shares outstanding | 9.98M | 32.45M |
| Employees | 16 | 115 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CELU has outperformed ATOS by 12.8 percentage points over the past year.
About Atossa Therapeutics
ATOS stock →Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
About Celularity
CELU stock →Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking.
Health Care · Biotechnology: Pharmaceutical Preparations · 115 employees
ATOS vs CELU FAQ
Which is bigger, Atossa Therapeutics or Celularity?
Atossa Therapeutics (ATOS) is larger, with a market capitalization of $15.92M compared with $15.02M for Celularity (CELU).
Which stock has performed better over the past year, ATOS or CELU?
CELU returned -73.54% over the past 12 months, compared with -86.37% for ATOS (price return, excluding dividends). Past performance does not predict future results.
Are Atossa Therapeutics and Celularity in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.